EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma

Shannon P Fortin Ensign, Robert B Jenkins, Caterina Giannini iD, Jann N Sarkaria iD, Evanthia Galanis iD, Sani H Kizilbash iD

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noac205 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Shannon P Fortin Ensign und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Astrocytoma, Brain Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, FDA HHS, U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isocitrate dehydrogenase (IDH) 1 or 2 mutations confer a favorable prognosis compared to IDH-wildtype in astrocytoma, frequently denoting a lower grade malignancy. However, recent molecular profiling has identified specific aggressive tumor subgroups with clear clinical prognostic implications that are independent of histologic grading. The homozygous deletion of CDKN2A/B is the strongest implicated independent indicator of the poor prognosis within IDH-mutant astrocytoma, and the identification of this alteration in these lower histologic grade tumors transforms their biology toward an aggressive grade 4 phenotype clinically. CDKN2A/B homozygous deletion is now sufficient to define a grade 4 tumor in IDH-mutant astrocytomas regardless of histologic appearance, yet there are currently no effective molecularly informed targeted therapies for these tumors. The biological impact of CDKN2A/B homozygous deletion in IDH-mutant tumors and the optimal treatment strategy for this molecular subgroup remains insufficiently explored. Here we review the current understanding of the translational significance of homozygous deletion of CDKN2A/B gene expression in IDH-mutant astrocytoma and associated diagnostic and therapeutic implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstrocytomaBrain NeoplasmsHumansCyclin-Dependent Kinase Inhibitor p16HomozygoteIsocitrate DehydrogenaseMutationSequence DeletionCyclin-Dependent Kinase Inhibitor p15

Stichwörter der Autor:innen

CDKN2A/BIDH-mutant astrocytomagrade 4 glioma

Substanzen

Cyclin-Dependent Kinase Inhibitor p16Isocitrate DehydrogenaseCDKN2A protein, humanCDKN2B protein, humanCyclin-Dependent Kinase Inhibitor p15

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Caterina Giannini, Jann N Sarkaria, Evanthia Galanis, Sani H Kizilbash

Förderung

  • NCI NIH HHS
  • FDA HHS
  • U.S. Food and Drug Administration
  • National Cancer Institute

Zitieren

APA

Fortin Ensign, S. P., Jenkins, R. B., Giannini, C., Sarkaria, J. N., Galanis, E., & Kizilbash, S. H. (2023). Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac205

Vancouver

Fortin Ensign SP, Jenkins RB, Giannini C, Sarkaria JN, Galanis E, Kizilbash SH. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac205

BibTeX
@article{FortinEnsign2023,
  author = {Fortin Ensign, Shannon P and Jenkins, Robert B and Giannini, Caterina and Sarkaria, Jann N and Galanis, Evanthia and Kizilbash, Sani H},
  title = {Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noac205}
}
Kostenlos starten →